The Molecular Mechanisms of Cognitive Dysfunction in Long COVID: A Narrative Review
-
Published:2025-05-26
Issue:11
Volume:26
Page:5102
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Popa Elena12ORCID, Popa Andrei Emilian3, Poroch Mihaela12, Poroch Vladimir1ORCID, Ungureanu Monica Iuliana12, Slanina Ana Maria12, Bacusca Agnes12, Coman Elena Adorata12
Affiliation:
1. Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Str., 700115 Iasi, Romania 2. Department of Family Medicine, Preventive Medicine and Interdisciplinary, “Grigore T. Popa” University of Medicine and Pharmacy, Universitatii Str. 16, 700115 Iasi, Romania 3. “Prof. Dr. Nicolae Oblu” Emergency Clinic Hospital, 700309 Iasi, Romania
Abstract
Cognitive dysfunction represents one of the most persistent and disabling features of Long COVID, yet its molecular underpinnings remain incompletely understood. This narrative review synthesizes current evidence on the pathophysiological mechanisms linking SARS-CoV-2 infection to long-term neurocognitive sequelae. Key processes include persistent neuroinflammation, blood–brain barrier (BBB) disruption, endothelial dysfunction, immune dysregulation, and neuroendocrine imbalance. Microglial activation and cytokine release (e.g., IL-6, TNF-α) promote synaptic dysfunction and neuronal injury, while activation of inflammasomes such as NLRP3 amplifies CNS inflammation. Vascular abnormalities, including microthrombosis and BBB leakage, facilitate the infiltration of peripheral immune cells and neurotoxic mediators. Hypothalamic–pituitary–adrenal axis dysfunction and reduced vagal tone further exacerbate systemic inflammation and autonomic imbalance. Biomarkers such as GFAP, NFL, IL-6, and S100B have been associated with both neuroinflammation and cognitive symptoms. Notably, transcriptomic signatures in Long COVID overlap with those observed in Alzheimer’s disease, highlighting shared pathways involving tau dysregulation, oxidative stress, and glial reactivity. Understanding these mechanisms is critical for identifying at-risk individuals and developing targeted therapeutic strategies. This review underscores the need for longitudinal research and integrative biomarker analysis to elucidate the molecular trajectory of cognitive impairment in Long COVID.
Reference169 articles.
1. Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset;Servier;Int. J. Infect. Dis.,2023 2. Long COVID: Major Findings, Mechanisms and Recommendations;Davis;Nat. Rev. Microbiol.,2023 3. Long COVID science, research and policy;Davis;Nat. Med.,2024 4. Reese, J.T., Blau, H., Casiraghi, E., Bergquist, T., Loomba, J.J., Callahan, T.J., Laraway, B., Antonescu, C., Coleman, B., and Gargano, M. (2023). Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes. EBioMedicine, 87. 5. World Health Organization (WHO) (2025, February 15). Post-COVID-19 Condition. Available online: https://www.who.int/europe/news-room/fact-sheets/item/post-COVID-19-condition.
|
|